NCT05303701 is a pivotal Phase 3 clinical trial conducted by Samsung Pharmaceutical Co., Ltd. evaluating the efficacy and safety of GV1001, a telomerase-derived peptide vaccine, for the treatment of moderate to severe Alzheimer's disease. This multi-center, randomized, double-blind, placebo-controlled trial represents a novel approach to AD treatment by targeting cellular senescence and promoting neuroprotection through telomerase-mediated mechanisms[1][2].
GV1001 represents a fundamentally different therapeutic strategy from the anti-amyloid antibodies that have dominated recent AD drug development. Rather than directly targeting amyloid or tau pathology, GV1001 aims to restore cellular function by activating telomerase, thereby addressing what many researchers consider a fundamental upstream contributor to neurodegeneration: cellular senescence and impaired neural stem cell function[3].
| Parameter | Value |
|---|---|
| NCT Number | NCT05303701 |
| Official Title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients With Moderate to Severe Alzheimer Disease |
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Sponsor | Samsung Pharmaceutical Co., Ltd. |
| Enrollment | 750 participants (Estimated) |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel |
| Masking | Double-blind |
| Start Date | July 1, 2027 |
| Primary Completion | July 1, 2031 |
| Last Updated | February 23, 2026 |
Key eligibility requirements include:
Cellular senescence is increasingly recognized as a key contributor to Alzheimer's disease pathogenesis. Senescent cells accumulate in the aging brain and exhibit a pro-inflammatory secretome (the senescence-associated secretory phenotype, SASP) that contributes to chronic neuroinflammation, neural stem cell dysfunction, and progressive neurodegeneration[4].
Key features of cellular senescence in AD include:
Telomerase is a ribonucleoprotein enzyme that maintains telomere length and has been shown to have protective effects in neurons beyond its canonical role in cellular aging. Research has demonstrated that telomerase:
The telomerase reverse transcriptase (TERT) component of telomerase has been shown to translocate to the nucleus in neurons and exert transcription-independent neuroprotective effects, making it an attractive therapeutic target[5].
GV1001 is a 16-amino acid peptide (KRVKWLRRMVRKRLVK) derived from the active site of the human telomerase reverse transcriptase (hTERT). This peptide is designed to:
The mechanism differs fundamentally from passive antibody therapies:
Preclinical studies in the 5xFAD mouse model demonstrated[1:1]:
GV1001 has undergone extensive clinical development:
| Phase | Indication | Key Findings |
|---|---|---|
| Phase 1/2 | Cancer (melanoma, lung) | Safety established, immunogenic |
| Phase 1/2 | AD | Dose-dependent immune response, good safety |
| Phase 2 | Moderate AD | Positive cognitive signals |
| Phase 3 | Moderate-severe AD | Currently enrolling |
The primary objectives are:
Change from baseline in SIB score at week 24 - The SIB is designed to assess cognitive function in patients with moderate to severe dementia
CIBIC-plus score at week 24 - Measures global change from baseline in overall functioning
GV1001 represents a fundamentally different approach to AD treatment:
| Approach | Target | Examples | Status |
|---|---|---|---|
| Anti-amyloid antibodies | Amyloid plaques | Lecanemab, Donanemab | Approved |
| Anti-tau antibodies | Tau tangles | Various in development | Phase 2/3 |
| Neurotransmitter modulators | Symptomatic | Donepezil, Memantine | Approved |
| Telomerase vaccine | Cellular senescence | GV1001 | Phase 3 |
By targeting cellular senescence and supporting neural stem cell function, GV1001 addresses mechanisms that may be upstream of classical amyloid and tau pathology[3:1].
This trial specifically targets patients with moderate to severe AD, a population with limited therapeutic options:
If successful, GV1001 would address a major gap in the AD treatment landscape.
Active immunization approaches for AD include[6]:
| Vaccine | Target | Approach | Stage |
|---|---|---|---|
| GV1001 | TERT | Telomerase activation | Phase 3 |
| ACI-35 | Phospho-tau | Liposome vaccine | Phase 1/2 |
| UB-311 | Amyloid-beta | Active immunization | Phase 2 |
| CAD106 | Amyloid-beta | Active immunization | Phase 2 |
Active vaccines offer potential advantages:
Based on previous clinical trials, the expected safety profile includes:
Common (Expected) Adverse Events:
Less Common:
The trial includes:
Positive results would represent a paradigm shift in AD treatment:
The trial may contribute to understanding:
Given its novel mechanism, GV1001 may be combinable with:
GV1001 (KRVKWLRRMVRKRLVK) is a 16-amino acid peptide derived from the active site of human telomerase reverse transcriptase (hTERT)[2:1]. The peptide is designed to:
The cellular immune response induced by GV1001 involves multiple populations[2:2]:
| Cell Type | Function | Key Mediators |
|---|---|---|
| CD4+ Helper T cells | Antigen recognition | IFN-γ, IL-2, IL-4 |
| CD8+ Cytotoxic T cells | Target cell killing | Perforin, Granzyme B |
| B cells | Antibody production | IgG, IgM |
| NK cells | Innate immunity | IFN-γ |
The immunogenicity of GV1001 is enhanced by:
Comprehensive schedule includes:
| Visit | Timing | Key Assessments |
|---|---|---|
| Screening | Days -28 to 0 | Medical history, cognitive testing |
| Baseline | Day 0 | SIB, MMSE, CIBIC, safety |
| Week 4 | Day 28 | SIB, MMSE, safety |
| Week 12 | Day 84 | SIB, MMSE, CIBIC, safety |
| Week 24 | Day 168 | SIB, MMSE, CIBIC, safety |
| Follow-up | Day 196 | Safety, long-term effects |
Primary efficacy analysis uses:
Moderate AD patients represent a substantial portion of the AD population:
| Feature | Value |
|---|---|
| Prevalence | ~40% of AD cases |
| Age | 70-80 years (median) |
| Disease duration | 3-6 years |
| CDR | 2 (moderate) |
Severe AD patients represent a challenging population:
| Feature | Value |
|---|---|
| Prevalence | ~20% of AD cases |
| Care needs | Extensive |
| Life expectancy | Reduced |
| Treatment options | Limited |
This population has historically been excluded from most clinical trials. GV1001's novel mechanism may offer benefits at advanced disease stages.
Telomere length may serve as a treatment response biomarker:
| Measure | Method | Utility |
|---|---|---|
| Leukocyte TL | qPCR | Population screening |
| Tissue TL | FISH | Research |
| Telomere ratio | Various | Response marker |
Studies have shown shortened telomere length in AD patients correlates with disease severity.
Treatment response may be assessed through inflammatory biomarkers:
| Marker | Source | Expected Change |
|---|---|---|
| IL-6 | Serum | Decrease |
| TNF-α | Serum | Decrease |
| S100B | CSF | Decrease |
| Feature | GV1001 | Passive Antibodies |
|---|---|---|
| Administration | Subcutaneous | Intravenous |
| Immune response | Active | Passive |
| Duration | Long-lasting | Finite |
| Boosters needed | Yes | No |
| Cost | Lower | Higher |
| Vaccine | Target | Stage | Mechanism |
|---|---|---|---|
| GV1001 | TERT | Phase 3 | Telomerase activation |
| ACI-35 | Phospho-tau | Phase 1/2 | Tau immunotherapy |
| UB-311 | Amyloid-β | Phase 2 | Amyloid immunotherapy |
| CAD106 | Amyloid-β | Phase 2 | Amyloid immunotherapy |
The trial requires:
Based on Phase 3 design:
| Milestone | Timeline |
|---|---|
| Topline data | 2031 |
| NDA submission | 2032 |
| Potential approval | 2033 |
Priority review may be available given the moderate-to-severe population unmet need.
NCT05303701 represents an important step in AD therapeutic development:
The success of GV1001 would validate telomerase-mediated neuroprotection as a therapeutic approach in neurodegeneration.
The scientific rationale for targeting telomerase in AD includes:
Positive results would enable:
Key factors for successful development:
| Factor | Description |
|---|---|
| Efficacy signal | Cognitive preservation at 6 months |
| Safety profile | No unexpected concerns |
| Biomarker correlation | Telomere/immune markers |
| Caregiver benefit | Reduced burden |
Cho YH, et al. Telomerase reverse transcriptase ameliorates Alzheimer-like pathology in 5xFAD mice. Nature Communications. 2019. ↩︎ ↩︎
Kim H, et al. GV1001, a telomerase-derived peptide vaccine: mechanisms and clinical applications. Journal of Translational Medicine. 2020. ↩︎ ↩︎ ↩︎
Lee J, et al. Telomere dysfunction in Alzheimer's disease pathogenesis. Ageing Research Reviews. 2023. ↩︎ ↩︎
Zhao W, et al. Cellular senescence and brain aging in neurodegenerative diseases. Cellular and Molecular Life Sciences. 2023. ↩︎
Mattson MP. Telomerase and neurogenesis in brain development and disease. Journal Alzheimer's Disease. 2003. ↩︎
Gonzalez C, et al. Therapeutic vaccines for Alzheimer's disease: progress and challenges. Lancet Neurology. 2023. ↩︎